408 related articles for article (PubMed ID: 20740617)
1. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry.
Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X;
Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726
[TBL] [Abstract][Full Text] [Related]
4. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
[TBL] [Abstract][Full Text] [Related]
5. Improvement in psoriasis during rituximab therapy for mixed cryoglobulinemia type II.
Moberg P; Charles JF; Respicio G; Venna SS; Rooney T
Cutis; 2010 Sep; 86(3):133-5. PubMed ID: 21049729
[TBL] [Abstract][Full Text] [Related]
6. Cryoglobulinemia vasculitis: an update.
Terrier B; Cacoub P
Curr Opin Rheumatol; 2013 Jan; 25(1):10-8. PubMed ID: 23196322
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of low-dose rituximab for mixed cryoglobulinemia.
Visentini M; Granata M; Veneziano ML; Borghese F; Carlesimo M; Pimpinelli F; Fiorilli M; Casato M
Clin Immunol; 2007 Oct; 125(1):30-3. PubMed ID: 17692572
[TBL] [Abstract][Full Text] [Related]
8. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C?
Ahmed MS; Wong CF
J Nephrol; 2007; 20(3):350-6. PubMed ID: 17557269
[TBL] [Abstract][Full Text] [Related]
9. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection.
Visentini M; Ludovisi S; Petrarca A; Pulvirenti F; Zaramella M; Monti M; Conti V; Ranieri J; Colantuono S; Fognani E; Piluso A; Tinelli C; Zignego AL; Mondelli MU; Fiorilli M; Casato M
Autoimmun Rev; 2011 Sep; 10(11):714-9. PubMed ID: 21570494
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry.
Bader-Meunier B; Decaluwe H; Barnerias C; Gherardi R; Quartier P; Faye A; Guigonis V; Pagnier A; Brochard K; Sibilia J; Gottenberg JE; Bodemer C;
J Rheumatol; 2011 Jul; 38(7):1436-40. PubMed ID: 21677003
[TBL] [Abstract][Full Text] [Related]
11. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.
Mekinian A; Ravaud P; Hatron PY; Larroche C; Leone J; Gombert B; Hamidou M; Cantagrel A; Marcelli C; Rist S; Breban M; Launay D; Fain O; Gottenberg JE; Mariette X
Ann Rheum Dis; 2012 Jan; 71(1):84-7. PubMed ID: 21926185
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.
Colantuono S; Mitrevski M; Yang B; Tola J; Carlesimo M; De Sanctis GM; Fiorilli M; Casato M; Visentini M
Clin Rheumatol; 2017 Mar; 36(3):617-623. PubMed ID: 28111716
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis.
Cohen C; Mekinian A; Saidenberg-Kermanac'h N; Stirnemann J; Fenaux P; Gherardi R; Fain O
Ann Rheum Dis; 2012 Apr; 71(4):628-9. PubMed ID: 22121135
[No Abstract] [Full Text] [Related]
15. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
[TBL] [Abstract][Full Text] [Related]
17. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
Novikov PI; Krivosheev OG; Semenkova EN
Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Russo A; Menegatti E; Baldovino S
Am J Nephrol; 2011; 34(2):175-80. PubMed ID: 21757891
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia.
Quartuccio L; Petrarca A; Mansutti E; Pieroni S; Calcabrini L; Avellini C; Zignego A; De Vita S
Clin Exp Rheumatol; 2010; 28(1 Suppl 57):84-7. PubMed ID: 20412709
[TBL] [Abstract][Full Text] [Related]
20. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
